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ABSTRACT 
Objective: Youth-onset type 2 diabetes is an emerging disease. We estimated incidence and prevalence trends of 
youth-onset type 2 diabetes between 2002 and 2013 in the Canadian province of British Columbia. 
Methods:  This population-based cohort study used a validated diabetes case-finding definition and algorithm to 
differentiate type 2 from type 1 diabetes to identify youth <20 years with type 2 diabetes within linked population-
based administrative data. Age-standardized incidence and prevalence were calculated. JoinPoint regression and 
double exponential smooth modeling were used. 
Results: From 2002/03-2012/13, the incidence of youth-onset type 2 diabetes increased from 3.45 (95% CI: 2,43, 
4.80) to 5.16 (95% CI: 3.86, 6.78)/100,000. The annual percent change (APC) in incidence was 3.74 (95% CI: 1.61, 
5.92; p=0.003) overall, while it was 5.94 (95% CI: 1.84, 10.20; p=0.009) and 0.53 (95% CI: -5.04, 6.43; p=0.837) in 
females and males, respectively. The prevalence increased from 0.009% (95% CI: 0.007, 0.011) in 2002/03 to 
0.021% (95% CI: 0.018, 0.024) in 2012/13 with an APC of 7.89 (95% CI: 6.41, 9.40; p<0.0001). In females, it 
increased from 0.012% (95% CI: 0.009, 0.015) to 0.027% (95% CI: 0.023, 0.032) and in males from 0.007% (95% 
CI: 0.005, 0.009) to 0.015% (95% CI: 0.012, 0.019). By 2030, we forecast a prevalence of 0.046% [95% CI: 0.043, 
0.048]. 
Conclusions: Youth-onset type 2 diabetes is increasing with higher rates in females versus males. If these rates 
continue, in 2030, the number of cases will increase by 5-fold. These data are needed to set priorities for diabetes 
prevention in youth. 
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INTRODUCTION 
Incidence rates of youth-onset type 2 diabetes vary worldwide. In the United States (2007), annual incidence 
rate was 9.0 cases per 100,000 youth 0-19 years of age per year, (1), while in Canada (2006-2008), the annual 
minimum incidence rate was 1.54 cases per 100,000 youth <18 years of age (2). The U.K and other European 
countries report much lower rates of youth-onset type 2 diabetes (3,4). Although the absolute number of cases of 
youth-onset type 2 diabetes appear inconsequential when compared to the number of cases in adults, the natural 
history of this emerging disease suggests youth-onset type 2 diabetes will significantly impact the health of children 
and youth today, and for generations to come.  
Youth-onset type 2 diabetes is materializing to be a more severe disease than adult-onset type 2 diabetes. As 
shown by the TODAY Study Group that conducted a clinical trial in the U.S to maintain glycemic control in youth-
onset type 2 diabetes, diabetes-related complications develop quickly (5,6) and are often present at diagnosis (2). 
SEARCH reported that, when compared to youth with type 1 diabetes, those with type 2 diabetes have a 
significantly increased higher odds of developing diabetic kidney disease, retinopathy, and peripheral neuropathy 
(7). Also, treatment of youth-onset type 2 diabetes with oral hypoglycemic agents is largely ineffective and almost 
50% of cases require subcutaneous insulin because of metabolic decompensation (8). Mortality is also higher in 
those who develop type 2 diabetes at a young age where an inverse relationship between age of diabetes onset and 
standardized mortality ratio (SMR) has been reported with the highest SMR (3.4 [95% CI 2.7-4.2]) in those 
diagnosed with diabetes between 15 and 30 years of age (9). 
Evidence suggests an increase in both incidence and prevalence of youth-onset type 2 diabetes, albeit at 
varying degrees depending on the population demographic. In the U.S., the overall prevalence of type 2 diabetes in 
youth <20 years increased by 30.5% between 2001 and 2009 (10), with predictions that the prevalence will increase 
by 178% by 2050 (11). Incidence rates are also on the rise in the U.S with an estimated relative increase of 4.8% 
(95% CI: 3.2, 6.4; p<0.001) per year between 2002/03 to 2011/12 (1). 
In Canada, administrative health data have been used to describe epidemiological trends of diabetes in youth 
(12), however, type 1 and type 2 diabetes are for the most part reported separately and therefore trends are assumed 
to reflect type 1 diabetes, the most common form of childhood diabetes. We have developed a validated algorithm 
for differentiating between type 1 and type 2 diabetes in administrative datasets using demographic and drug 
utilization data (13) and have recently reported incidence and prevalence trends of childhood type 1 diabetes (14). 
The objective of this study was to describe trends in the incidence and prevalence of youth-onset type 2 diabetes in a 
population-based sample of Canadian youth <20 years of age.  
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METHODS 
Data source:  
We used four datasets that exist within a universal health care system in the Canadian province of British 
Columbia.  These databases are linkable using an individual’s personal health number (PHN) and include: (i) client 
registration information (Client Registry & Premium Billing); (ii) physician fee-for-service claims for outpatient 
services (Medical Services Plan – MSP); (iii) health claims for hospital admissions (Discharge Abstract Database – 
DAD); and (iv) provincial prescription dispensations (PharmaNet). To establish the Diabetes Database, a diabetes 
case-finding definition was applied to the linked data where an individual with any 1 of following within a 1-year 
period was included: 1 hospital discharge code for diabetes; 2 outpatient physician MSP claims coded for diabetes; 2 
or more prescription dispensations for insulin; 2 or more prescription dispensations for an oral anti-diabetic 
medication (except metformin); or two of more of: 1 prescription dispensation for insulin, 1 prescription 
dispensation for an oral anti-diabetic medication, 2 prescriptions for metformin and 1 outpatient physician MSP 
claim coded as diabetes. Once individuals were included in the Diabetes Database, they remained in it until they 
moved out of the province or died. For the purpose of this study, data was retrieved on individuals <20 years of age 
within the Diabetes Database. The diabetes case-finding definition used to create the Diabetes Database has been 
shown to be highly sensitive (97%) in the <20 year old population when validated against a clinical database 
comprised of physician-diagnosed pediatric type 1 and type 2 diabetes (15).  
Study population and period:  
In this population-based study examining an average of 950,000 individuals <20 years of age each year, we 
included all individuals >1 year of age and <20 years of age in the Diabetes Database between April 1st, 2002 to 
March 31st, 2013 who were classified as having type 2 diabetes within the province of British Columbia. A case was 
classified as type 2 diabetes if they were 10 years of age or older, and their prescription dispensations within 2 years 
(730 days) of meeting the case-finding algorithm (the index date) included an oral anti-diabetic medication (i.e. 
metformin, sulfonylurea) alone or in combination with insulin, ± glucose strips. This diabetes differentiating 
algorithm was 83.2% sensitive and 97.5% specific in classifying cases of type 2 diabetes in individuals <20 years of 
age, with a positive predictive value of 73.7%, when compared to a gold standard clinical database of physician-
diagnosed pediatric type 1 and type 2 diabetes (13). Individuals who did not show evidence of diabetes-related 
prescription dispensations within 2 years (730 days) of their index date were excluded from the analysis (Figure 1).  
Definition of main outcomes:  
We identified incident and prevalent cases for each fiscal year (April 1st to March 31st) from 2002 to 2013, 
based on the following definitions. Incident cases: (i) the individual met the conditions of the diabetes case-finding 
algorithm for the first time, and the date at which this occurred was the index date for diagnosis; and (ii) the 
individual met the conditions of the diabetes differentiating algorithm as a case of type 2 diabetes. Prevalent cases: 
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cases that existed at the beginning of that fiscal year that met the conditions of the diabetes differentiating algorithm 
as a case of type 2 diabetes, in addition to incident cases that were identified during that year.  
Statistical analysis:  
Age-standardized incidence (per 100,000) and prevalence rates (per 100) were calculated using 1990/91 
Canadian population as the standard population and Census data (StatsCan) on the BC population <20 years of age. 
The JoinPoint regression analysis program (V4.3.1.0) was used to examine the trends in age-standardized incidence 
and prevalence rates, overall, and by gender. We used the permutation test (with 5000 randomly permuted datasets) 
method in the Joinpoint program that selects the best fitting piecewise continuous log-linear model (16) at a 
significance level of 0.05 to calculate the annual percent change (APC) with corresponding 95% confidence 
intervals. We also used double exponential smooth modeling in SAS [9.4] to project the number and prevalence 
rates of type 2 diabetes until 2030. 
RESULTS 
Incidence of youth-onset type 2 diabetes: 
In 2002/03, 37 (62% female) new cases of youth-onset type 2 diabetes were identified increasing to 53 (68% 
female) new cases in 2012/13. Incidence was 3.45 (95% CI: 2.43, 4.80) per 100,000 in 2002/03 and 5.16 (95% CI: 
3.86, 6.78) per 100,000 in 2012/13. During the same time period, incidence increased from 4.43 (95% CI: 2.81, 
6.74) to 7.21 (95% CI: 5.05, 10.05) in females and from 2.53 (95% CI: 1.39, 4.36) to 3.23 (95% CI: 1.88, 5.24) in 
males (Table 1 - online). The sex differences in type 2 diabetes incidence widened after 2010 (Figure 2A). 
The APC in incidence was 3.74 (95% CI: 1.61, 5.92; p=0.003) overall, while it was 5.94 (95% CI: 1.84, 
10.20; p=0.009) and 0.53 (95% CI: -5.04, 6.43; p=0.837) in females and males, respectively. While the overall APC 
did not increase in males, there was a marginally significant increase in the APC between 2002-2007 (APC: 11.95, 
95% CI: 0.15, 25.14; p=0.048), and a marginally significant decrease between 2007-2012 (APC: -9.62, 95% CI: -
18.7, 0.49; p=0.058). The APC in the overall population was the highest from 2002-2008 (APC: 6.35, 95% CI: 2.31, 
10.55; p=0.008). Incidence was highest among females (Figure 3C) and youth aged 15-19 years (Figure 3D) where 
it increased from 10.57 (95% CI: 7.13, 15.09) in 2002/03 to 13.81 (95% CI: 9.82, 18.88) in 2012/13 (Table 1 - 
online).  
Prevalence of youth-onset type 2 diabetes: 
From 2002/03 to 2012/13, prevalent cases increased from 97 (63% female) to 219 (63% Female) and 
prevalence increased from 0.009% (95% CI: 0.007, 0.011) to 0.021% (95% CI: 0.018, 0.024) representing a 2.3-fold 
increase over a decade. In the same time period, prevalence increased from 0.012% (95% CI: 0.009, 0.015) to 
0.027% (95% CI: 0.023, 0.032) in females, and from 0.007% (95% CI: 0.005, 0.009) to 0.015% (95% CI: 0.012, 
0.019) in males (Table 2 -online).  
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The APC in the overall prevalence was 7.89 (95% CI: 6.41, 9.40; p<0.0001), while the same for females and 
males was 7.98 (95% CI: 6.94, 9.02; p<0.0001) and 7.77 (95% CI: 4.09, 11.57; p=0.001), respectively. Prevalence 
increased at a much higher rate from 2002-2008 (APC: 10.84, 95% CI: 8.64, 13.08, p<0.0001) followed by a slower 
increase thereafter (APC: 3.86, 95% CI: 0.80, 7.0, p=0.021).   A significant increase in prevalence was also found 
among females aged 10-14 years. 
Projections of youth-onset type 2 diabetes prevalence through 2020:  
Assuming similar rates and APC, the projected total number of prevalent cases of youth-onset type 2 diabetes 
will increase to 350 (95% CI: 326, 374) in 2020, 421 (95% CI: 394, 447) in 2025 and 491 (95% CI: 462, 519) in 
2030, representing more than a 5-fold increase in the number of prevalent cases of type 2 diabetes in children since 
2002/03. The prevalence will increase to 0.046% (95% CI: 0.043, 0.048) by 2030 (Figure 4). 
DISCUSSION 
To our knowledge, this study is the first of its kind to use administrative health data to describe trends in 
youth-onset type 2 diabetes. We report an increasing trend in the incidence and prevalence of youth-onset type 2 
diabetes over the last decade in a population-based sample of Canadian youth, with distinct sex differences where 
young females are affected more than males. The majority of the burden of youth-onset type 2 diabetes was in the 
15-19 year age bracket although, an increasing trend in prevalence among females aged 10-14 years was also 
observed. If current rates continue, the prevalence of youth-onset type 2 diabetes will increase by 5-fold by the year 
2030.  
A similar increase in youth-onset type 2 diabetes has been reported in the U.S. and among First Nation youth 
in Canada. The SEARCH study reported that overall prevalence of youth-onset type 2 diabetes in the U.S rose from 
0.034% in 2001 to 0.046% in 2009, representing a 35% relative increase when adjusted for differences in 
completeness of ascertainment (10). In the same U.S population, unadjusted incidence rate of youth-onset type 2 
diabetes increased by 7.1% annually (p<0.001) from 2002/03 to 2011/12 (1). In Canadian First Nation youth <18 
years of age, the incidence of type 2 diabetes doubled over a 5-year period (9.03 to 20.58 cases per 100,000 youth 
per year) (17). European data shows little or no increase in youth-onset type 2 diabetes (18) however, surveillance 
has typically excluded youth aged 15-19 years, the age bracket that faces the highest burden of disease. Austria 
recently reported a stable incidence of type 2 diabetes in youth ≤15 years of age from 1999 to 2015 (4). 
The Canadian Diabetes Association first published clinical practice guidelines on the management of youth-
onset type 2 diabetes in 2003 with updates in 2008 and 2013. Our data showed the highest incidence rate (5.85 cases 
per 100,000/year) in 2008 and the highest APC (6.35) from 2002-2008, suggesting that increased awareness of and 
screening for youth-onset type 2 diabetes has contributed to the increasing epidemiological trends. Rising rates of 
overweight and obesity also likely contribute to this finding.  The prevalence of overweight and obesity doubled 
among Canadians aged 12-17 years over 25 years (1978/79-2004), and obesity alone tripled (19). In a study of 
Canadian youth with new-onset type 2 diabetes, 95% were obese and the remaining were overweight, confirming 
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obesity as a key risk factor for youth-onset type 2 diabetes (2). Recent data suggest a decline in the prevalence of 
overweight and obesity in Canadian children from 30.7% to 27% (p<0.001) from 2009 to 2013 (20), which may 
translate into declining trends of youth-onset type 2 diabetes in the future. Recent data released by Statistics Canada 
comparing rates of childhood obesity in 2004 versus 2015 showed that in the province of British Columbia, obesity 
rates decreased more in males (16.8% in 2004 to 11.1% in 2015) than in females (11% in 2004 to 9.1% in 2015) 
(StatsCan - http://www5.statcan.gc.ca), possibly explaining the sex differences in incidence trends of youth-onset 
type 2 diabetes in our region.   
Our data show a 3:1 female predominance for youth-onset type 2 diabetes in 2012/13, and a widening gap in 
incidence between males and females since 2005. These sex differences have been described in the literature, and 
across all ethnic groups (10,17,21). Interestingly, in adults, the opposite has been reported; globally, 15.6 million 
more men than women had diabetes in 2015 (22). There continues to be a considerable gap in knowledge on the 
complex interplay of hormones, genes, lifestyle and environment that might contribute to the sex differences in rates 
of youth-onset type 2 diabetes, and why this trend reverses in adulthood. Insulin resistance during puberty can be as 
much as 30% greater in girls compared to boys (23) and a recent study by Cooper et al showed that pubertal females 
have a 30-40% higher insulinaemic response to a high glycemic index meal compared to pubertal males (24). These 
sex differences may partly be explained by higher adiposity in pubertal females versus males (25,26). Increased 
prevalence of youth-onset type 2 diabetes in females 15 years of age and older may also be due to more frequent 
screening and/or recognition of type 2 diabetes as part of the pre-natal medical assessment. Lastly, our data may 
have inadvertently captured young females with polycystic ovarian syndrome treated with metformin where the 
physician incorrectly used a diabetes diagnostic code. 
Higher rates of type 2 diabetes in females entering child-bearing age has significant implications and requires 
an immediate public health response. The TODAY trial reported on female youth with type 2 diabetes (mean 
diabetes duration of 3 years) who became pregnant (N=53 pregnancies). Among these pregnancies, almost 25% 
resulted in fetal loss and 2 ended in stillbirth. Of the pregnancies resulting in a live-born infant, 15% were preterm 
and 20% had a major congenital anomaly (27). There is also strong evidence supporting that fetal over-nutrition and 
a hyperglycemic intrauterine environment increases the risk of obesity and early-onset type 2 diabetes in the 
offspring, resulting in a vicious cycle that may be contributing to increasing rates of youth-onset type 2 diabetes 
(28). In Canada, incidence rates of both gestational and pre-gestational diabetes doubled from 1996-2010 in women 
aged 15-50 years (29). Rising rates of youth-onset type 2 diabetes will add to this increasing burden of diabetes in 
pregnancy.  
This study has several strengths: it is population-based, includes 11 years of data, and is the first to 
differentiate between type 2 from type 1 diabetes in administrative data enabling the delineation of epidemiological 
trends for youth-onset type 2 diabetes at a population level. Limitations of our study include the inability to describe 
trends by ethnicity and the potential for misclassifying cases of type 2 diabetes as type 1 diabetes and vice versa. 
The absence of clinical information within administrative data such as pancreatic antibody levels makes 
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classification of diabetes type more challenging. Also, in a validation study using a combination of electronic 
medical record (EMR) and administrative data to identify and classify youth with diabetes, 9% of youth with 
physician diagnosed type 1 diabetes used metformin and insulin (30). In our study, these children would be 
misclassified as type 2 diabetes, potentially overestimating our rates. However, in our previous validation research, 
algorithms to differentiate type 1 vs. type 2 diabetes that classified insulin plus metformin users as type 1 diabetes 
performed less favorably compared to algorithms that classified this drug utilization pattern as type 2 diabetes (13). 
Our algorithm also assumed that individuals under 10 years of age had type 1 diabetes, potentially underestimating 
type 2 diabetes rates because, although type 2 diabetes under 10 years of age is uncommon, in some studies, it has 
accounted for roughly 10% of youth-onset type 2 diabetes cases (2,17). Children with existing type 2 diabetes that 
moved to BC from another province would have been counted as an incident (rather than a prevalent) case because 
we do not have access to data from other Canadian provinces. Lastly, our forecasting model, although similar to our 
observed data, should be interpreted with caution as it is based on only 11 years of data, assumes no change in 
clinical practice that could result in the identification of more (or less) cases, and does not take into account the 
recent data indicating decreasing rates of overweight and obesity in Canadian children (StatsCan).  
Youth-onset type 2 diabetes is increasing at an alarming rate and if prevention efforts are not given priority 
among public health officials, the number of cases in British Columbia, Canada will increase by 5-fold by the year 
2030. British Columbia has some of the lowest rates of childhood obesity and overweight in Canada, and therefore, 
rates in other provinces are likely at least similar, if not higher than what is reported here. The greatest burden of 
youth-onset type 2 diabetes is in older youth aged 15-19 years who likely access primary, rather than pediatric care. 
Therefore, increasing awareness of youth-onset type 2 diabetes among primary care practitioners is critical to ensure 
early identification and initiation of management so as to prevent serious diabetes-related complications and early 
mortality. The female predominance is particularly concerning considering the impact of maternal obesity and 
diabetes during pregnancy on the metabolic health of future offspring. Our findings will inform resource allocation 
for health services and public health, and ongoing surveillance will help to assess the impact of diabetes prevention 
initiatives designed for youth. Further research is needed to examine factors contributing to rising rates of youth-
onset type 2 diabetes, as well as the pathophysiological and environmental mechanisms leading to the observed sex 
differences. 
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Figure 2: Age standardized incidence (A) and prevalence (B) rates by sex and year 
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Figure 3: Incident and prevalent cases by sex and age group 
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Figure 4: Projections of youth-onset type 2 diabetes prevalence through 2030 
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Supplementary Materials 
Table 1; online only: Age-Standardized and Age-Specific Incidence Rates (per 100,000 [95% CI]) of T2D in youth 10-19 years of age 
 
 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 
All youth            
n 37 46 41 47 47 51 62 50 54 57 53 
Population  963,702 958,746 952,680 950,240 946,336 944,855 943,889 941,654 941,102 937,895 932,268 
Total Incidence 3.45  
[2.43-4.80] 
4.32 
[3.17-5.81] 
3.84 
[2.75-5.25] 
4.36 
[3.20-5.84] 
4.36 
[3.21-5.85] 
4.77 
[3.55-6.31] 
5.84 
[4.48-7.53] 
4.67 
[3.47-6.20] 
5.14 
[3.86-6.74] 
5.37 
[4.06-6.99] 
5.16 
[3.86-6.78] 
Incidence by age            
10-14 years 2.61 
[1.05-5.38] 
6.72 
[3.98-10.62] 
4.87 
[2.59-8.33] 
4.13 
[2.06-7.40] 
4.56 
[2.36-7.96] 
6.16 
[3.52-10.01] 
8.23 
[5.09-12.58] 
4.41 
[2.20-7.89] 
6.15 
[3.44-10.14] 
3.75 
[1.71-7.12] 
5.92 
[3.24-9.93] 
15-19 years 10.57 
[7.13-15.09] 
9.81 
[6.52-14.18] 
9.79 
[6.50-14.14] 
12.51 
[8.77-17.33] 
12.11 
[8.43-16.84] 
12.05 
[8.39-16.76] 
14.11 
[10.13-19.14] 
13.43 
[9.55-18.36] 
13.48 
[9.58-18.42] 
16.75 
[12.35-22.21] 
13.81 
[9.82-18.88] 
Females            
n 23 27 24 26 29 20 42 27 39 41 36 
Population  468,690 466,038 463,355 462,186 460,276 459,304 458,858 457,844 457,359 456,062 453,124 
Total Incidence 4.43 
[2.81-6.74] 
5.21 
[3.43-7.68] 
4.63 
[2.97-6.99] 
4.93 
[3.22-7.33] 
5.49  
[3.67-7.98] 
3.87 
[2.36-6.07] 
8.08 
[5.82-11.00] 
5.20 
[3.43-7.65] 
7.52 
[5.35-10.36] 
7.95 
[5.70-10.85] 
7.21 
[5.05-10.05] 
Incidence by age            
10-14 years 3.83 
[1.24-8.94] 
6.91 
[2.16-13.11] 
6.18 
[2.67-12.17] 
3.10 
[0.84-7.94] 
3.14 
[0.85-8.03] 
5.56 
[2.24-11.46] 
8.88 
[4.43-15.89] 
4.95 
[1.82-10.77] 
5.89 
[2.37-12.13] 
5.13 
[1.88-11.16] 
7.81 
[3.57-14.83] 
15-19 years 13.07 
[7.75-20.66] 
13.00 
[7.71-20.55] 
11.51 
[6.58-18.69] 
15.73 
[9.86-23.82] 
17.81 
[11.52-26.29] 
9.22 
[4.91-15.77] 
21.99 
[14.94-31.22] 
14.92 
[9.24-22.81] 
22.84 
[15.62-32.34] 
25.22 
[17.56-35.07] 
19.74 
[13.01-28.73] 
Males            
n 14 19 17 21 18 31 20 23 15 16 17 
Population  494,993 492,694 489,312 488,041 486,050 485,543 485,024 483,806 483,740 481,830 479,142 
Total Incidence 2.53  
[1.39-4.36] 
3.49 
[2.10-5.55] 
3.09 
[1.80-5.05] 
3.82 
[2.36-5.93] 
3.30 
[1.96-5.31] 
5.61 
[3.81-8.05] 
3.74 
[2.28-5.85] 
4.17 
[2.64-6.34] 
2.90 
[1.62-4.84] 
2.94 
[1.68-4.86] 
3.23 
[1.88-5.24] 
Incidence by age            
10-14 years 1.45 
[0.18-5.25] 
6.54 
[2.99-12.42] 
3.64 
[1.18-8.50] 
5.11 
[2.05-10.52] 
5.89 
[2.54-11.61] 
6.73 
[3.08-12.77] 
7.61 
[3.65-14.00] 
3.90 
[1.27-9.11] 
6.40 
[2.76-12.60] 
2.44 
[0.50-7.12] 
4.12 
[1.34-9.61] 
15-19 years 8.22 
[4.25-14.36] 
6.81 
[3.26-12.51] 
8.16 
[4.21-14.25] 
9.47 
[5.18-15.89] 
6.73 
[3.23-12.37] 
14.71 
[9.22-22.28] 
6.68 
[3.21-12.29] 
12.03 
[7.13-19.01] 
4.69 
[1.89-9.66] 
8.80 
[4.68-15.04] 
8.24 
[4.26-14.39] 
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Table 2; online only: Age-Standardized and Age-Specific Prevalence (per 100) [95% CI] of T2D in youth 10-19 years of age 
 
 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 
All youth            
n 97 118 133 144 160 174 194 198 202 221 219 
Population  963,762 958,818 952,772 950,337 946,449 944,978 944,021 941,802 941,250 938,059 932,434 
Total Prevalence 0.009 
[0.007-0.011] 
0.011 
[0.009-0.013] 
0.012 
[0.010-0.015] 
0.013 
[0.011-0.016] 
0.015 
[0.013-0.017] 
0.016 
[0.014-0.019] 
0.018 
[0.016-0.021] 
0.018 
[0.016-0.021] 
0.019 
[0.016-0.022] 
0.021 
[0.018-0.024] 
0.021 
[0.018-0.024] 
Prevalence by age            
10-14 years 0.004 
[0.002-0.007] 
0.009 
[0.005-0.013] 
0.009 
[0.006-0.014] 
0.010 
[0.007-0.015] 
0.013 
[0.009-0.018] 
0.014 
[0.010-0.019] 
0.015 
[0.011-0.020] 
0.013 
[0.009-0.018] 
0.015 
[0.010-0.020] 
0.009 
[0.005-0.013] 
0.011 
[0.008-0.017] 
15-19 years 0.030 
[0.024-0.037] 
0.033 
[0.027-0.041] 
0.038 
[0.031-0.046] 
0.041 
[0.034-0.049] 
0.044 
[0.036-0.052] 
0.047 
[0.040-0.056] 
0.054 
[0.046-0.063] 
0.057 
[0.049-0.067] 
0.057 
[0.049-0.067] 
0.070 
[0.060-0.080] 
0.068 
[0.059-0.078] 
Females            
N 61 73 78 81 91 88 107 105 115 131 137 
Population  468,728 466,084 463,409 462,241 460,338 459,372 458,923 457,922 457,435 456,152 453,225 
Total Prevalence 0.012 
[0.009-0.015] 
0.014 
[0.011-0.018] 
0.015 
[0.012-0.019] 
0.015 
[0.012-0.019] 
0.017 
[0.014-0.021] 
0.017 
[0.013-0.021] 
0.020 
[0.017-0.025] 
0.020 
[0.016-0.024] 
0.022 
[0.018-0.027] 
0.025 
[0.021-0.030] 
0.027 
[0.023-0.032] 
Prevalence by age            
10-14 years 0.005 
[0.002-0.011] 
0.009 
[0.005-0.016] 
0.010 
[0.005-0.017] 
0.010 
[0.005-0.017] 
0.013 
[0.007-0.020] 
0.013 
[0.007-0.021] 
0.015 
[0.009-0.024] 
0.016 
[0.009-0.024] 
0.018 
[0.011-0.027] 
0.012 
[0.007-0.020] 
0.015 
[0.009-0.024] 
15-19 years 0.039 
[0.029-0.051] 
0.044 
[0.034-0.057] 
0.047 
[0.036-0.060] 
0.049 
[0.038-0.062] 
0.053 
[0.042-0.067] 
0.051 
[0.040-0.064] 
0.062 
[0.050-0.077] 
0.061 
[0.049-0.075] 
0.067 
[0.054-0.082] 
0.084 
[0.070-0.101] 
0.088 
[0.073-0.105] 
Males            
N 36 45 55 63 69 86 87 93 87 90 82 
Population  495,015 492,720 489,350 488,083 486,101 485,598 485,091 483,876 483,812 481,904 479,207 
Total Prevalence 0.007 
[0.005-0.009] 
0.008 
[0.006-0.011] 
0.010 
[0.007-0.013] 
0.011 
[0.009-0.015] 
0.012 
[0.010-0.016] 
0.015 
[0.012-0.019] 
0.016 
[0.013-0.019] 
0.017 
[0.013-0.020] 
0.016 
[0.013-0.020] 
0.016 
[0.013-0.020] 
0.015 
[0.012-0.019] 
Prevalence by age            
10-14 years 0.003 
[0.001-0.007] 
0.008 
[0.004-0.014] 
0.009 
[0.005-0.015] 
0.010 
[0.006-0.017] 
0.013 
[0.008-0.021] 
0.015 
[0.009-0.023] 
0.014 
[0.009-0.023] 
0.010 
[0.005-0.017] 
0.012 
[0.007-0.020] 
0.006 
[0.002-0.012] 
0.008 
[0.004-0.015] 
15-19 years 0.022 
[0.015-0.031] 
0.023 
[0.016-0.032] 
0.029 
[0.021-0.039] 
0.033 
[0.025-0.044] 
0.034 
[0.026-0.045] 
0.044 
[0.034-0.056] 
0.045 
[0.035-0.058] 
0.053 
[0.042-0.067] 
0.048 
[0.038-0.061] 
0.056 
[0.045-0.070] 
0.049 
[0.039-0.062] 
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